|Bid||1.52 x 1200|
|Ask||1.59 x 800|
|Day's Range||1.5000 - 1.5900|
|52 Week Range||1.4900 - 7.9500|
|Beta (3Y Monthly)||3.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.00|
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 6) Gritstone Oncology Inc (NASDAQ: GRTS ) Down In The Dumps ...
Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.
Shares of Conatus Pharmaceuticals Inc. plummeted 53% Thursday after the company announced its Phase 2 clinical trial of emricasan did not meet its primary endpoint. Patients with liver damage from nonalcoholic fatty liver disease did not show sufficient patient improvement on the drug compared to a placebo. Stifel analysts downgraded the company to hold from buy and lowered their price target to $4 from $10, while analysts at SunTrust Robinson Humphrey lowered their price target to $12 from $20. Friday's selloff puts the biotech's stock on track to suffer its biggest one-day percentage decline since the company went public in July 2013. Shares of Conatus have fallen 53% in the year to date, and the S&P 500 has fallen 0.1%.
NEW YORK, NY / ACCESSWIRE / December 6, 2018 / U.S. markets fell in Tuesday amidst trade related uncertainty between the U.S. and China. The Dow Jones Industrial Average fell 3.10 percent to close at 25,027.07, ...
Conatus Pharmaceuticals Inc. (CNAT) today announced top-line results from the company’s Phase 2b ENCORE-PH clinical trial showing clinically meaningful treatment effects in compensated NASH cirrhosis patients at high risk of decompensation. The trial’s primary endpoint was change in mean hepatic venous pressure gradient (HVPG) from baseline to Week 24 in any of three emricasan dosing groups compared with placebo. In the overall trial population, changes in HVPG from baseline to Week 24 showed trends consistently favoring emricasan compared with placebo but did not meet the primary endpoint.
Conatus Pharmaceuticals Inc’s (NASDAQ:CNAT): Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. With Read More...
NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Investors need to pay close attention to Conatus (CNAT) stock based on the movements in the options market lately.
Poster #1226, “Multicenter, double-blind, randomized trial of emricasan in subjects post liver transplantation (LT) with recurrent hepatitis C virus (HCV) and liver fibrosis or cirrhosis despite achieving sustained virologic response (SVR),” will be displayed by Catherine Frenette, M.D., (Scripps Clinic, La Jolla, CA) in the Liver Transplantation: Viral Hepatitis section on Saturday, November 10, from 2:00 p.m. to 7:30 p.m. PT, in the Moscone Center Poster Hall – Hall C. Presentation #251A, highlighting selected content from poster #1226, will be delivered by K. Rajinder Reddy, M.D., (University of Pennsylvania Medical Center, Philadelphia, PA) in the Parallel 37: Liver Transplantation: Alcohol and Hepatitis C session on Monday, November 12, at 3:15 p.m. PT, in the Moscone Center Room 153/155.
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / Conatus Pharmaceuticals and Titan Pharmaceuticals were both seeing gains in Friday’s trading session. There was no news to explain Titan shares jumping but Conatus reported third quarter results and an update on its trials last week. Conatus Pharmaceuticals Inc. shares closed up 19.63% on about 1.8 million shares traded on Friday.
Conatus (CNAT) delivered earnings and revenue surprises of 0.00% and -20.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had a loss of 15 cents per share. The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was also ...
SAN DIEGO, Nov. 01, 2018 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat.
Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Thursday, November 1, 2018, to discuss the financial results and provide a corporate update. A live and archived audio webcast of the call will also be available in the Investors section of the Conatus website at www.conatuspharma.com. In collaboration with Novartis, Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease.
Conatus Pharmaceuticals (CNAT) needs investors to pay close attention to the stock based on moves in the options market lately.
SAN DIEGO, Oct. 02, 2018 -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that two abstracts – one addressing clinical results with the company’s pan-caspase.
NEW YORK, NY / ACCESSWIRE / September 25, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company, focused on the development and commercialization of novel medicines for the treatment of liver diseases. On September 17th, CNAT shares closed at $4.16 per share and had an average trading volume under 500K. Conatus is in a collaboration agreement with Novartis for the development of its lead drug candidate emricasan (IDN-6556).
Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, will host an invitation-only symposium on portal hypertension for institutional investors and research analysts on Thursday, September 27, 2018, from 4:30 p.m. to 6:00 p.m. ET in New York. Guadalupe Garcia-Tsao, M.D., Professor of Medicine in the Section of Digestive Diseases at Yale School of Medicine, Director of the Clinical and Translational Core at Yale Liver Center, and Chief of the Section of Digestive Diseases at the Veterans Administration-Connecticut Health Care System, will address the clinical importance of portal hypertension.
NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to ...
Conatus Pharmaceuticals Inc. (CNAT) has accepted invitations to participate in two upcoming investor conferences. At the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease (September 26-27 in New York), senior management will conduct a series of scheduled meetings with investment professionals. At the Roth Capital Partners Battle of the NASH Thrones Investor Conference (October 17 in New York), senior management will conduct a series of scheduled meetings with investment professionals and participate in a panel discussion on fibrotic, inflammatory and metabolic agents.